Explained | What is a heterologous booster vaccine, and what are its advantages? - The Hindu
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study -
DCGI approves Biological E's COVID-19 vaccine Corbevax as heterologous booster dose | Zee Business
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
What is a heterologous booster COVID vaccine, and why should you take this jab?, ET HealthWorld
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 | Nature Communications
Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine
![Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7113e2_JJBoosterVE_IMAGE_29March22_1200x675.jpg?_=89755 "Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...")
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...
SII seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults, ET HealthWorld
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults - India Today
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases
EU Medicines Agency on X: "‼️ EMA & @ECDC_EU share their recommendations on the possibility of using 2 different #COVID19vaccines, either for the 1st and 2nd doses of a primary course, or
NTAGI holds meeting on Covovax inclusion as heterologous booster on CoWin portal, ET HealthWorld
iNCOVACC World's first Intranasal Vaccine to receive both Primary series & Heterologous booster approval | DD News
Govt panel likely to decide on Covovax as a heterologous booster dose for adults on Wednesday, ET HealthWorld
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
Corbevax gets DCGI nod as heterologous Covid booster dose for adults | Mint
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Heterologous COVID-19 booster doses show 68 percent effectiveness
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
